藥物專利無效案件中單方委託實驗報告認定的考量因素  

Factors Considered in Identification of Unilaterally Commissioned Experimental Reports in Drug Patent Invalidation Cases

作　　者：王冬 王熒 Wang Dong;Wang Ying(the Reexamination and Invalidation Department of the Patent Office,CNiPA;the Examination Department of Pharmaceutical and Biological Inventions of the Patent Office,CNiPA)

机构地区：[1]國家知識産權局專利局複審和無效審理部 [2]國家知識産權局專利局醫藥生物發明審查部

出　　处：《中国专利与商标》2025年第1期47-57,共11页China Patents & Trademarks

摘　　要：—、弓言醫藥行業屬於高風險、高投入、高回報的行業,由於專利具有獨佔權這一法律屬性,因此申請專利保護是醫藥行業最爲有效的知識産權保護方式之一。而對於醫藥領域的專利申請,發明能否霣施及可達到的技術效果通常難以直接預測和判斷。I.Introduction The pharmaceutical industry is a high-risk,high-investment and high-return industry.Since patents have the legal attribute of exclusivity,applying for patents is one of the most effective ways to protect intellectual property rights in the pharmaceutical industry.However,as for a patent application in the pharmaceutical field,it is usually difficult to directly predict and judge whether the invention can be implemented and whether the technical effect thereof can be achieved.

关 键 词：發明霣施 專利保護 知識産權 醫藥行業 單方委託實驗報告 考量因素 藥物專利無效 技術效果 

分 类 号：D923.42[政治法律—民商法学]